{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T14:34:31Z","timestamp":1793457271063,"version":"4.5.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2014,3,1]],"date-time":"2014-03-01T00:00:00Z","timestamp":1393632000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/2.5"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"published-print":{"date-parts":[[2014,3]]},"DOI":"10.1007\/s40262-013-0126-x","type":"journal-article","created":{"date-parts":[[2014,1,15]],"date-time":"2014-01-15T08:21:36Z","timestamp":1389774096000},"page":"213-225","source":"Crossref","is-referenced-by-count":212,"title":["Pharmacokinetic and Pharmacodynamic Profile of Empagliflozin, a Sodium Glucose Co-Transporter\u00a02 Inhibitor"],"prefix":"10.1007","volume":"53","author":[{"given":"Andr\u00e9 J.","family":"Scheen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,3,1]]},"reference":[{"key":"126_CR1","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1152\/physrev.00055.2009","volume":"91","author":"EM Wright","year":"2011","unstructured":"Wright EM, Loo DD, Hirayama BA. Biology of human sodium glucose transporters. Physiol Rev. 2011;91:733\u201394.","journal-title":"Physiol Rev"},{"key":"126_CR2","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1152\/physrev.1994.74.4.993","volume":"74","author":"MA Hediger","year":"1994","unstructured":"Hediger MA, Rhoads DB. Molecular physiology of sodium\u2013glucose cotransporters. Physiol Rev. 1994;74:993\u20131026.","journal-title":"Physiol Rev"},{"key":"126_CR3","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1210\/er.2010-0029","volume":"32","author":"MA Abdul-Ghani","year":"2011","unstructured":"Abdul-Ghani MA, Norton L, Defronzo RA. Role of sodium\u2013glucose cotransporter 2 (SGLT 2) inhibitors in the treatment of type 2 diabetes. Endocr Rev. 2011;32:515\u201331.","journal-title":"Endocr Rev"},{"key":"126_CR4","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1210\/jc.2011-2260","volume":"97","author":"J Bolinder","year":"2012","unstructured":"Bolinder J, Ljunggren O, Kullberg J, et al. Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin. J Clin Endocrinol Metab. 2012;97:1020\u201331.","journal-title":"J Clin Endocrinol Metab"},{"key":"126_CR5","first-page":"S313","volume":"55","author":"S Toubro","year":"2012","unstructured":"Toubro S, Cefalu WT, Xie J, et al. Canagliflozin, a sodium glucose co-transporter 2 inhibitor, reduces body weight mainly through loss of fat mass in subjects with type 2 diabetes [abstract no. 762]. Diabetologia. 2012;55:S313.","journal-title":"Diabetologia"},{"key":"126_CR6","unstructured":"Bristol Myers Squibb-AstraZeneca EEIG. Summary of product characteristics: Forxiga 5\u00a0mg & 10\u00a0mg film coated tablets. Electronic Medicines Compendium. http:\/\/www.medicines.org.uk\/emc\/medicine\/27188\/SPC\/Forxiga+5 mg++%26+10+mg+film+coated+tablets\/ . Accessed 17 Jul 2013."},{"key":"126_CR7","unstructured":"Janssen Pharmaceuticals Inc. INVOKANA\u2122 (canagliflozin) tablets, for oral use [prescribing information] (issued March 2013). http:\/\/www.invokanahcp.com\/prescribing-information.pdf . Accessed 17 Jul 2013."},{"key":"126_CR8","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1111\/j.1463-1326.2011.01517.x","volume":"14","author":"R Grempler","year":"2012","unstructured":"Grempler R, Thomas L, Eckhardt M, et al. Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors. Diabetes Obes Metab. 2012;14:83\u201390.","journal-title":"Diabetes Obes Metab"},{"key":"126_CR9","doi-asserted-by":"publisher","first-page":"2154","DOI":"10.2337\/dc12-2391","volume":"36","author":"D Polidori","year":"2013","unstructured":"Polidori D, Sha S, Mudaliar S, et al. Canagliflozin lowers postprandial glucose and insulin by delaying intestinal glucose absorption in addition to increasing urinary glucose excretion: results of a randomized, placebo-controlled study. Diabetes Care. 2013;36:2154\u201361.","journal-title":"Diabetes Care"},{"key":"126_CR10","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/j.clinthera.2013.01.010","volume":"35","author":"B Zambrowicz","year":"2013","unstructured":"Zambrowicz B, Ding ZM, Ogbaa I, et al. Effects of LX4211, a dual SGLT1\/SGLT2 inhibitor, plus sitagliptin on postprandial active GLP-1 and glycemic control in type 2 diabetes. Clin Ther. 2013;35:273\u201385.","journal-title":"Clin Ther"},{"key":"126_CR11","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1124\/jpet.113.203364","volume":"345","author":"DR Powell","year":"2013","unstructured":"Powell DR, Smith M, Greer J, et al. LX4211 increases serum glucagon-like peptide 1 and peptide YY levels by reducing sodium\/glucose cotransporter 1 (SGLT1)-mediated absorption of intestinal glucose. J Pharmacol Exp Ther. 2013;345:250\u20139.","journal-title":"J Pharmacol Exp Ther"},{"key":"126_CR12","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1111\/j.1463-1326.2011.01518.x","volume":"14","author":"L Thomas","year":"2012","unstructured":"Thomas L, Grempler R, Eckhardt M, et al. Long-term treatment with empagliflozin, a novel, potent and selective SGLT-2 inhibitor, improves glycaemic control and features of metabolic syndrome in diabetic rats. Diabetes Obes Metab. 2012;14:94\u20136.","journal-title":"Diabetes Obes Metab"},{"key":"126_CR13","first-page":"A282","volume":"62","author":"HU H\u00e4ring","year":"2013","unstructured":"H\u00e4ring HU, Merker L, Seewaldt-Becker E, et al. Empagliflozin as add-on to metformin for 24\u00a0weeks improves glycemic control in patients with type 2 diabetes (T2DM) [abstract no. 1092-P]. Diabetes. 2013;62 Suppl 1:A282.","journal-title":"Diabetes."},{"key":"126_CR14","doi-asserted-by":"publisher","first-page":"3396","DOI":"10.2337\/dc12-2673","volume":"36","author":"HU H\u00e4ring","year":"2013","unstructured":"H\u00e4ring HU, Merker L, Seewaldt-Becker E, et al. Empagliflozin as add-on to metformin plus sulfonylurea in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial. Diabetes Care. 2013;36:3396\u2013404. doi: 10.2337\/dc12-2673 .","journal-title":"Diabetes Care"},{"issue":"2","key":"126_CR15","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1111\/dom.12188","volume":"16","author":"C. S. Kovacs","year":"2013","unstructured":"Kovacs CS, Seshiah V, Swallow R, et al. Empagliflozin improves glycaemic and weight control as add-on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: a 24-week, randomized, placebo-controlled trial. Diabetes Obes Metab. Epub 2013 Aug 1. doi: 10.1111\/dom.12188 .","journal-title":"Diabetes, Obesity and Metabolism"},{"key":"126_CR16","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/S2213-8587(13)70084-6","volume":"1","author":"M Roden","year":"2013","unstructured":"Roden M, Weng J, Eilbracht J, et al. Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Diabetes Endocrinol. 2013;1:208\u201319. doi: 10.1016\/S2213-8587(13)70084-6 .","journal-title":"Lancet Diabetes Endocrinol"},{"key":"126_CR17","first-page":"A285","volume":"62","author":"J Rosenstock","year":"2013","unstructured":"Rosenstock J, Jelaska A, Kim G, et al. Empagliflozin as add-on to basal insulin for 78\u00a0weeks improves glycemic control with weight loss in insulin-treated (T2DM) [abstract no. 1102-P]. Diabetes. 2013;62 Suppl 1:A285.","journal-title":"Diabetes."},{"key":"126_CR18","first-page":"LB21","volume":"62","author":"G Kim","year":"2013","unstructured":"Kim G, Gerich JE, Salsali A, et al. Empagliflozin (EMPA) increases genital infections but not urinary tract infections (UTIs) in pooled data from four pivotal phase III trials [abstract no. 74-LB]. Diabetes. 2013;62 Suppl 1:LB21.","journal-title":"Diabetes."},{"key":"126_CR19","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1002\/cpdd.16","volume":"2","author":"L Seman","year":"2013","unstructured":"Seman L, Macha S, Nehmiz G, et al. Empagliflozin (BI 10773), a potent and selective SGLT2 inhibitor, induces dose-dependent glucosuria in healthy subjects. Clin Pharmacol Drug Dev. 2013;2:152\u201361.","journal-title":"Clin Pharmacol Drug Dev"},{"key":"126_CR20","doi-asserted-by":"publisher","first-page":"213","DOI":"10.2133\/dmpk.DMPK-12-RG-082","volume":"28","author":"A Sarashina","year":"2013","unstructured":"Sarashina A, Koiwai K, Seman LJ, et al. Safety, tolerability, pharmacokinetics and pharmacodynamics of single doses of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in healthy Japanese subjects. Drug Metab Pharmacokinet. 2013;28:213\u20139.","journal-title":"Drug Metab Pharmacokinet"},{"key":"126_CR21","doi-asserted-by":"publisher","first-page":"873","DOI":"10.5414\/CP201948","volume":"51","author":"S Macha","year":"2013","unstructured":"Macha S, Jungnik A, Hohl K, et al. Effect of food on the pharmacokinetics of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, and assessment of dose proportionality in healthy volunteers. Int J Clin Pharmacol Ther. 2013;51:873\u20139.","journal-title":"Int J Clin Pharmacol Ther"},{"issue":"2","key":"126_CR22","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1007\/s13300-013-0030-2","volume":"4","author":"Tim Heise","year":"2013","unstructured":"Heise T, Seman L, Macha S, et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of multiple rising doses of empagliflozin in patients with type 2 diabetes mellitus. Diabetes Ther. Epub 2013 Jul 10. doi: 10.1007\/s13300-013-0030-2 .","journal-title":"Diabetes Therapy"},{"key":"126_CR23","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1111\/dom.12073","volume":"15","author":"T Heise","year":"2013","unstructured":"Heise T, Seewaldt-Becker E, Macha S, et al. Safety, tolerability, pharmacokinetics and pharmacodynamics following 4\u00a0weeks\u2019 treatment with empagliflozin once daily in patients with type 2 diabetes. Diabetes Obes Metab. 2013;15:613\u201321.","journal-title":"Diabetes Obes Metab"},{"issue":"3","key":"126_CR24","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1111\/dom.12182","volume":"16","author":"S. Macha","year":"2013","unstructured":"Macha S, Mattheus M, Halabi A, et al. Pharmacokinetics, pharmacodynamics and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in subjects with renal impairment. Diabetes Obes Metab. Epub 2013 Jul 16. doi: 10.1111\/dom.12182 .","journal-title":"Diabetes, Obesity and Metabolism"},{"key":"126_CR25","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1517\/17425255.2013.777428","volume":"9","author":"AJ Scheen","year":"2013","unstructured":"Scheen AJ. Pharmacokinetic considerations for the treatment of diabetes in patients with chronic kidney disease. Expert Opin Drug Metab Toxicol. 2013;9:529\u201350. doi: 10.1517\/17425255.2013.777428 .","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"2","key":"126_CR26","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1111\/dom.12183","volume":"16","author":"S. Macha","year":"2013","unstructured":"Macha S, Rose P, Mattheus M, et al. Pharmacokinetics, safety and tolerability of empagliflozin, a sodium glucose cotransporter 2 inhibitor, in patients with hepatic impairment. Diabetes Obes Metab. Epub 2013 Jul 16. doi: 10.1111\/dom.12183 .","journal-title":"Diabetes, Obesity and Metabolism"},{"key":"126_CR27","first-page":"A614","volume":"61","author":"T Giessmann","year":"2012","unstructured":"Giessmann T, Heise T, Macha S, et al. Lack of interaction between the sodium glucose cotransporter-2 inhibitor empagliflozin and hydrochlorothiazide or torasemide in patients with T2DM [abstract no. 2440-PO]. Diabetes. 2012;61:A614.","journal-title":"Diabetes"},{"key":"126_CR28","doi-asserted-by":"publisher","first-page":"132","DOI":"10.5414\/CP201794","volume":"51","author":"S Macha","year":"2013","unstructured":"Macha S, Dieterich S, Mattheus M, et al. Pharmacokinetics of empagliflozin, a sodium glucose cotransporter-2 (SGLT2) inhibitor, and metformin following co-administration in healthy volunteers. Int J Clin Pharmacol Ther. 2013;51:132\u201340.","journal-title":"Int J Clin Pharmacol Ther"},{"key":"126_CR29","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1007\/s12325-012-0055-3","volume":"29","author":"T Brand","year":"2012","unstructured":"Brand T, Macha S, Mattheus M, et al. Pharmacokinetics of empagliflozin, a sodium glucose cotransporter-2 (SGLT-2) inhibitor, coadministered with sitagliptin in healthy volunteers. Adv Ther. 2012;29:889\u201399.","journal-title":"Adv Ther"},{"key":"126_CR30","doi-asserted-by":"publisher","first-page":"A33","DOI":"10.1016\/j.clinthera.2012.12.002","volume":"35","author":"C Friedrich","year":"2013","unstructured":"Friedrich C, Metzmann K, Rose P, et al. A randomized, open-label, crossover study to evaluate the pharmacokinetics of empagliflozin and linagliptin after coadministration in healthy male volunteers. Clin Ther. 2013;35:A33\u201342.","journal-title":"Clin Ther"},{"key":"126_CR31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.7243\/2050-0866-1-1","volume":"1","author":"S Macha","year":"2012","unstructured":"Macha S, Mattheus M, Pinnetti S, et al. Pharmacokinetics of empagliflozin, a sodium glucose cotransporter 2 inhibitor, and glimepiride following co-administration in healthy volunteers: a randomised, open-label, crossover study. Diabetes Res Clin Metab. 2012;1:1\u20137.","journal-title":"Diabetes Res Clin Metab"},{"key":"126_CR32","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1111\/dom.12028","volume":"15","author":"S Macha","year":"2013","unstructured":"Macha S, Rose P, Mattheus M, et al. Lack of drug\u2013drug interaction between empagliflozin, a sodium glucose cotransporter 2 inhibitor, and warfarin in healthy volunteers. Diabetes Obes Metab. 2013;15:316\u201323.","journal-title":"Diabetes Obes Metab"},{"key":"126_CR33","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1016\/j.clinthera.2013.02.015","volume":"35","author":"S Macha","year":"2013","unstructured":"Macha S, Sennewald R, Rose P, et al. Lack of clinically relevant drug\u2013drug interaction between empagliflozin, a sodium glucose cotransporter 2 inhibitor, and verapamil, ramipril, or digoxin in healthy volunteers. Clin Ther. 2013;35:226\u201335.","journal-title":"Clin Ther"},{"key":"126_CR34","first-page":"228","volume":"3","author":"S Macha","year":"2012","unstructured":"Macha S, Lang B, Pinnetti S, et al. Lack of pharmacokinetic interaction between the sodium glucose cotransporter-2 (SGLT-2) inhibitor empagliflozin and simvastatin in healthy volunteers [abstract no. PCS-33-7]. J Diabetes Investig. 2012;3:228.","journal-title":"J Diabetes Investig"},{"key":"126_CR35","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1007\/s40261-013-0068-y","volume":"33","author":"S Macha","year":"2013","unstructured":"Macha S, Mattheus M, Pinnetti S, et al. Effect of empagliflozin on the steady-state pharmacokinetics of ethinylestradiol and levonorgestrel in healthy female volunteers. Clin Drug Investig. 2013;33:351\u20137.","journal-title":"Clin Drug Investig"},{"key":"126_CR36","doi-asserted-by":"crossref","unstructured":"Scheen AJ. Evaluating SGLT-2 inhibitors for type 2 diabetes: pharmacokinetic and toxicological considerations. Expert Opin Drug Metab Toxicol. 2013 (in press).","DOI":"10.1517\/17425255.2014.873788"},{"key":"126_CR37","doi-asserted-by":"publisher","first-page":"262","DOI":"10.7326\/0003-4819-159-4-201308200-00007","volume":"159","author":"D Vasilakou","year":"2013","unstructured":"Vasilakou D, Karagiannis T, Athanasiadou E, et al. Sodium\u2013glucose cotransporter 2 inhibitors for type 2 diabetes: a systematic review and meta-analysis. Ann Intern Med. 2013;159:262\u201374. doi: 10.7326\/0003-4819-159-4-201308200-00007 .","journal-title":"Ann Intern Med"},{"key":"126_CR38","doi-asserted-by":"publisher","first-page":"S378","DOI":"10.1007\/s00125-012-2785-9","volume":"56","author":"SE Inzucchi","year":"2013","unstructured":"Inzucchi SE, Zinman B, Lachin JM, et al. Design of the empagliflozin cardiovascular outcome event trial in type 2 diabetes mellitus [abstract no. 944]. Diabetologia. 2013;56:S378.","journal-title":"Diabetologia"},{"key":"126_CR39","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1186\/1475-2840-12-129","volume":"12","author":"M Ridderstr\u00e5le","year":"2013","unstructured":"Ridderstr\u00e5le M, Svaerd R, Zeller C, et al. Rationale, design and baseline characteristics of a 4-year (208-week) phase III trial of empagliflozin, an SGLT2 inhibitor, versus glimepiride as add-on to metformin in patients with type 2 diabetes mellitus with insufficient glycemic control. Cardiovasc Diabetol. 2013;12:129. doi: 10.1186\/1475-2840-12-129 .","journal-title":"Cardiovasc Diabetol"}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40262-013-0126-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-013-0126-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-013-0126-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-013-0126-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,6]],"date-time":"2019-08-06T11:40:13Z","timestamp":1565091613000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40262-013-0126-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,3]]},"references-count":39,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2014,3]]}},"alternative-id":["126"],"URL":"https:\/\/doi.org\/10.1007\/s40262-013-0126-x","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"value":"0312-5963","type":"print"},{"value":"1179-1926","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,3]]}}}